Drugs / Pelareorep
Pelareorep
also known as
REOLYSIN · Wild-type Reovirus · Reovirus Type 3 Dearing · Mammalian orthoreovirus 3-dearing · PELA · PO BB0209 · Previously REOLYSIN · Reovirus 3 (strain dearing) · +2 more
Trials 31 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04102618 | Mar 2019 → Apr 2022 | breast cancer | Oncolytics Biotech | Terminated | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT05519059 | Oct 2021 → Sep 2022 | breast cancer | Adlai Nortye Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT03605719 | Oct 2018 → Oct 2022 | plasma cell myeloma | Emory University | Completed | No outcome recorded |
| Phase 1 | NCT03015922 | Jun 2017 → Sep 2021 | plasma cell myeloma | University of Leeds | Unknown | No outcome recorded |
| Phase 1 | NCT02723838 | Feb → Sep 2017 | infiltrating bladder urothelial carcinoma | Oncolytics Biotech | Withdrawn | No outcome recorded |
| Phase 1 | NCT02620423 | Dec 2015 → Mar 2018 | pancreatic adenocarcinoma | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 1 | NCT02514382 | Aug 2015 → Apr 2022 | plasma cell myeloma | University of Southern California | Completed | No outcome recorded |
| Phase 1 | NCT02444546 | Jun 2015 → Jul 2018 | anaplastic oligodendroglioma, atypical teratoid rhabdoid tumor, childhood astrocytic tumor, childhood medulloblastoma +3 | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02101944 | Dec 2014 → May 2021 | anemia, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01533194 | Apr 2012 → Feb 2015 | light chain deposition disease, plasma cell myeloma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT01274624 | Dec 2010 → Feb 2018 | colorectal cancer | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 1 | NCT01240538 | Dec 2010 → Apr 2014 | childhood malignant neoplasm | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00602277 | Apr 2008 → Aug 2016 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00528684 | Jul 2006 → Apr 2010 | malignant glioma | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT05514990 | Oct 2022 → Dec 2026 expected | plasma cell myeloma | University of Southern California | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT07280377 | Oct 2021 → Jul 2027 expected | anal squamous cell carcinoma, pancreatic ductal adenocarcinoma | Oncolytics Biotech | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT03282188 | Oct 2017 → Jul 2018 | melanoma, skin cancer | University of Leeds | Withdrawn | No outcome recorded |
| Phase 214 trials | ||||||
| Phase 2 | NCT07446322 | Apr 2026 → Aug 2027 expected | colorectal cancer | Oncolytics Biotech | Recruiting | No outcome recorded |
| Phase 2 | NCT04445844 | Jul 2020 → Jun 2025 overdue | female breast carcinoma, triple-negative breast carcinoma | Mridula George, MD | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04215146 | Jun 2020 → Aug 2022 overdue | breast carcinoma | Oncolytics Biotech | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03723915 | Nov 2018 → Dec 2019 | pancreatic adenocarcinoma | Northwestern University | Terminated | No outcome recorded |
| Phase 2 | NCT01656538 | Feb 2013 → Nov 2016 | breast cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01199263 | Dec 2010 → Jun 2015 | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT01280058 | Dec 2010 → Jan 2016 | pancreatic acinar cell carcinoma, pancreatic ductal adenocarcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00998192 | Oct 2009 → Sep 2013 | squamous cell lung carcinoma | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00998322 | Oct 2009 → Dec 2013 | pancreatic adenocarcinoma | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00984464 | Sep 2009 → Feb 2014 | metastatic melanoma | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00861627 | Mar 2009 → Sep 2015 | non-small cell lung carcinoma | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00753038 | Aug 2008 → Jul 2011 | head and neck squamous cell carcinoma | Oncolytics Biotech | Completed | No outcome recorded |
| Phase 2 | NCT00651157 | Apr 2008 → Dec 2011 | melanoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 2 | NCT00503295 | Jun 2007 → Feb 2011 | Ewing sarcoma/peripheral primitive neuroectodermal tumor, fibrosarcoma, leiomyosarcoma, osteosarcoma +2 | Oncolytics Biotech | Completed | No outcome recorded |
Also used as a comparator or background therapy in 4 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 23 trials | ||||||
| Phase 2 | NCT01619813 Comparator | Dec 2012 → Apr 2016 | prostate cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01708993 Comparator | Dec 2012 → Jan 2016 | non-small cell lung carcinoma | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 2 | NCT01622543 Comparator | Oct 2012 → Jan 2017 | colorectal cancer | Canadian Cancer Trials Group | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01166542 Comparator | Jun 2010 → Apr 2012 | head and neck squamous cell carcinoma | Oncolytics Biotech | Completed | No outcome recorded |
Evidence & citations 13 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | pelareorep | “OBJECTIVES: Pelareorep (reolysin), a Dearing strain of reovirus serotype 3, has demonstrated oncolytic activity as single agent and synergy with chemotherapy.” PMID 29748010 ↗ Mar 201813“Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity.” PMID 37812476 ↗ Dec 2023 “Randomized Phase 2 Trial of the Oncolytic Virus Pelareorep (Reolysin) in Upfront Treatment of Metastatic Pancreatic Adenocarcinoma.” PMID 27039845 ↗ Apr 2016 “Patients also receive Pelareorep IV over 60 minutes on days 1, 2, 3, and 8 in course 1 and on days 1 and 8 of subsequent courses.” NCT03723915 ↗ |
| Known as | Mammalian orthoreovirus 3-dearing | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545069 ↗ |
| Known as | PELA | “Our preclinical studies showed that the oncolytic reovirus formulation pelareorep (PELA) has significant immunomodulatory anti-myeloma activity.” PMID 37812476 ↗ Dec 2023 |
| Known as | PO BB0209 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545069 ↗ |
| Known as | Previously REOLYSIN | “Previously REOLYSIN®” NCT04102618 ↗ |
| Known as | REOLYSIN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02723838 ↗ |
| Known as | Reovirus 3 (strain dearing) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545069 ↗ |
| Known as | Reovirus Serotype 3 - Dearing Strain | “Reovirus Serotype 3 - Dearing Strain (REOLYSIN®) is a naturally occurring, ubiquitous, non-enveloped human reovirus.” NCT02723838 ↗ |
| Known as | Reovirus type 3 (strain dearing) | ChEMBL registry synonym — accepted as the source's own label CHEMBL3545069 ↗ |
| Known as | Reovirus Type 3 Dearing | “A Phase 2 Study of Intravenous Administration of REOLYSIN (Reovirus Type 3 Dearing) in Combination With Paclitaxel and Carboplatin in Patients With Metastatic Melanoma” NCT00984464 ↗1“REOLYSIN® (Reovirus Type 3 Dearing)” NCT00998192 ↗ |
| Known as | Wild-type Reovirus | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01533194 ↗ |
| Modality | Other / unclassified | “unmodified oncolytic reovirus” NCT00503295 ↗ |
| Route | Intravenous | “given intravenously” NCT00503295 ↗ |